Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Fintel reports that on December 11, 2024, Wells Fargo initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Your digestive system does more than just process food—it’s home to trillions of tiny organisms, mostly bacteria, that play a ...

Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for ...

Difficile Oct. 17, 2024 — A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C.

The gut microbiota might perhaps one day become a routine tool for the early diagnosis of many diseases and to guide ...

In the largest study of its kind in the UK, a research team from Queen’s University Belfast have discovered a new way to ...

which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical ...

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind ...

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.1% during the third quarter, according to ...